CHICAGO, July 5, 2024 /PRNewswire/ -- The global contrast medial injectors market is expected to grow from USD 1.6 billion in 2024 to USD 2.3 billion by 2029, at a CAGR of 8.0%. Key drivers include the rising incidence of cancer and cardiovascular diseases, especially among the aging population, and advancements in injector technology that enhance diagnostic accuracy and early detection. Increased disposable incomes and expanding healthcare access in emerging markets also contribute to this growth. However, the high cost of contrast media injectors poses a restraint, particularly for smaller healthcare facilities in emerging economies. Opportunities arise from rising healthcare expenditure in countries like China, India, Brazil, and Mexico, driven by government initiatives and increasing demand for advanced healthcare services. Challenges include a shortage of trained professionals to operate advanced medical devices. The market is segmented by product, type, application, and end user, with consumables, dual-head injectors, radiology applications, and hospitals holding the largest shares in their respective categories. North America is expected to remain the largest market due to its technological leadership and robust healthcare infrastructure. Key market players include Bayer AG, Bracco Imaging S.p.A., Guerbet, MEDTRON AG, Ulrich GmbH & CO. KG, and Nemoto Kyorindo Co., Ltd.

MarketsandMarkets Logo

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96046959

Browse in-depth TOC on "Contrast Media Injectors Market"

180 - Tables
50 - Figures
206 - Pages

Key Players in the Contrast Media Injectors Market: A Competitive Landscape

The contrast media injectors market is consolidated, with key players adopting strategies such as partnerships, acquisitions, and expansions to maintain their market positions. As of 2023, the major players in this market include Bayer AG (Germany), Bracco Imaging S.p.A. (Italy), Guerbet (France), Medtron AG (Germany), Ulrich GmbH & Co. KG (Germany), and Nemoto Kyorindo (Japan).

Bayer AG (Germany): Global Leader in Radiology Business

Bayer Pharma, a subgroup of Bayer AG, focuses on the radiology business and operates in over 100 countries worldwide. The company offers digital solutions, injection systems, and contrast agents, along with related accessories and consumables for contrast media injectors. Bayer emphasizes R&D in pharmaceuticals to address high medical needs and leverages its global presence to maintain a strong market position.

Bracco Imaging S.p.A. (Italy): Innovator in Diagnostic Imaging

Bracco Imaging S.p.A., part of the Bracco Group, is a global leader in diagnostic imaging. The company manufactures and commercializes contrast media injectors and software, including contrast agents. Bracco focuses on strategic collaborations and innovation for organic growth. Notably, Bracco partnered with Ulrich GmbH to market its MR injector in the US. The company operates manufacturing sites in multiple regions, maintaining a presence in over 100 countries with a robust R&D capability and strong product portfolio.

Guerbet (France): Pioneer in Contrast Media Injectors

Guerbet offers contrast media injectors and related accessories through its Diagnostic Imaging segment. The company prioritizes launching innovative solutions to enhance patient outcomes. Committed to R&D, Guerbet introduced OptiProtect 3S in 2021 to support imaging centers. Operating in Europe, Asia, and the Americas, Guerbet distributes its products in about 80 countries, continually driving market growth through technological advancements and new product launches.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=96046959

Product Segmentation: Consumables Lead the Market

The contrast media injectors market is segmented based on product into injector systems, consumables, and accessories. The consumables segment is expected to hold the major market share in 2023, driven by the cost-effectiveness of treatments and increasing awareness of the benefits of contrast-mediated procedures.

Type Segmentation: Dual-Head Injectors Dominate

By type, the market is segmented into dual-head, single-head, and syringeless injectors. In 2023, the dual-head segment held a significant market share, supported by a favorable reimbursement scenario in developed countries and the advantages of dual-head injectors over other types.

Application Segmentation: Radiology Holds a Significant Share

The contrast media injectors market is segmented by application into interventional cardiology, radiology, and interventional radiology. In 2023, the radiology segment held a significant market share, driven by the growing global prevalence of cancer and increasing regulatory approvals of contrast agents.

End User Segmentation: Hospitals Lead the Market

Regarding end users, the market is fragmented into hospitals and diagnostic imaging centers. The hospitals segment attributed the major share of the market in 2023, driven by a rising focus on healthcare research and increasing funding opportunities from public and private organizations.

Geographical Insights: North America Leads with Significant Share

The contrast media injectors market is segmented by region into North America, Europe, Asia Pacific, Latin America, and MEA. In 2023, North America accounted for the major market share, followed by Europe and APAC. This significant share is attributed to the increasing installation of diagnostic imaging equipment, a rising number of contrast-mediated scans, a higher incidence of target diseases, and expanding research activities.

For more information, inquire now! Inquire Now

Related Reports:

Contrast Media Market

Preclinical Imaging Market

Diagnostic Imaging Market

Nuclear Medicine Market

Diagnostic Imaging Services Market

Get access to the latest updates on Contrast Media Injectors Companies and Contrast Media Injectors Market Share

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/global-contrast-media-injectors-market-to-reach-usd-2-3-billion-by-2029-driven-by-automated-solutions--marketsandmarkets-302189888.html

Copyright 2024 PR Newswire